German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it ...

By Ludwig Burger (Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion ...

The plan is to bring the two biotech companies together to develop transformative cancer treatments, BioNTech said.

BioNTech has agreed to acquire mRNA specialist CureVac for approximately $1.25bn, as the big pharma company amps up its ...

Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed ...

The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...

BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline.

Following the closing of the transaction, CureVac's operating subsidiary will become a wholly owned subsidiary of BioNTech.

BioNTech SE agreed to buy former Covid vaccine rival CureVac NV for about $1.25 billion in an all-stock transaction that will ...

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The acquisition boosts BioNTech’s mRNA design and manufacturing capabilities, accelerating development of next-gen cancer ...